PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer
N. Zhang(Wuhan University), Conghua Xie(Wuhan University), Zihang Zeng(Hunan University of Science and Technology), Yan Gong(Guizhou University of Finance and Economics), J Zhang(Wuhan University), Jing Li(Wuhan University), Jing Zhang(Peking University), Yanyan Luo(Wuhan University), Xupin Jiang(Wuhan University), Yanping Gao(Nanjing General Hospital of Nanjing Military Command)
Cited by 32
Related Papers
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
|JAMA Oncology|2020|1.1k
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
|Journal of Hematology & Oncology|2022|178
TRIM38 inhibits TNFα- and IL-1β–triggered NF-κB activation by mediating lysosome-dependent degradation of TAB2/3
|Proceedings of the National Academy of Sciences|2014|151
Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity
|Molecular Cell|2021|128
The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment
|Cellular Physiology and Biochemistry|2016|115